Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Feb 1;61(2):492-8.
doi: 10.1016/j.ijrobp.2004.05.051.

Radiotherapy for local control of osteosarcoma

Affiliations

Radiotherapy for local control of osteosarcoma

Thomas F DeLaney et al. Int J Radiat Oncol Biol Phys. .

Abstract

Purpose: Local control of osteosarcoma in patients for whom a resection with satisfactory margins is not achieved can be difficult. This study evaluated the efficacy of radiotherapy (RT) in this setting.

Methods and materials: We identified 41 patients in our sarcoma database with osteosarcomas that either were not resected or were excised with close or positive margins and who underwent RT with external beam photons and/or protons at our institution between 1980 and 2002. Patient charts were reviewed to assess local control, progression-free survival, metastasis-free survival, and overall survival.

Results: The anatomic sites treated were head/face/skull in 17, extremity in 8, spine in 8, pelvis in 7, and trunk in 1. Of the 41 patients, 27 (65.85%) had undergone gross total tumor resection, 9 (21.95%) subtotal resection, and 5 (12.2%) biopsy only. The radiation dose ranged from 10 to 80 Gy (median 66). Twenty-three patients (56.1%) received a portion of their RT with protons. Chemotherapy was given to 35 patients (85.4%). Of the 41 patients, 27 (65.85%) were treated for localized disease at primary presentation, 10 (24.4%) for local recurrence, and 4 (9.8%) for metastatic disease. The overall local control rate at 5 years was 68% +/- 8.3%. The local control rate according to the extent of resection was 78.4% +/- 8.6% for gross total resection 77.8% +/- 13.9% for subtotal resection, and 40% +/- 21.9% for biopsy only (p < 0.01). The overall survival rate according to the extent of resection was 74.45% +/- 9.1% for gross total resection, 74.1% +/- 16.1% for subtotal resection, and 25% +/- 21.65% for biopsy only (p < 0.001). Patients with either gross or subtotal resection had a greater rate of local control, survival, and disease-free survival compared with those who underwent biopsy only at 5 years (77.7% +/- 7.5% vs. 40% +/- 21% [p <0.001], 73.9% +/- 8.1% vs. 25% +/- 21.6% [p <0.001], and 51.9% +/- 9.1% vs. 25% +/- 21.6% [p <0.01], respectively). Overall survival was better in patients treated at primary presentation (78.8% +/- 8.6% compared with 54% +/- 17.3% for recurrence) p <0.05). No definitive dose-response relationship for local control of tumor was seen, although the local control rate was 71% +/- 9% for 32 patients receiving doses > or =55 Gy vs. 53.6% +/- 20.1% for 9 patients receiving <55 Gy (p = 0.11). Of 15 patients with tumors >5.3 cm, 9 received doses > or =55 Gy and the local control rate was 80% +/- 17.9%, and 6 received doses <55 Gy with a local control rate of only 50% +/- 25% at 5 years (p = 0.16). Among patients who underwent gross total resection, the local control rate was 77.5% +/- 9.95% in 22 patients with negative margins vs 66.7% +/- 27.2% in 3 patients with positive margins (p = 0.54). Two patients had unknown margin status.

Conclusion: RT can help provide local control of osteosarcoma for patients in whom surgical resection with widely, negative margins is not possible. It appears to be more effective in situations in which microscopic or minimal residual disease is being treated.

PubMed Disclaimer

Similar articles

Cited by

  • Diaphyseal Tibial Osteosarcoma With Myiasis.
    Saluja HK, Jadhav S. Saluja HK, et al. Cureus. 2022 Dec 20;14(12):e32718. doi: 10.7759/cureus.32718. eCollection 2022 Dec. Cureus. 2022. PMID: 36686136 Free PMC article.
  • Autophagy and its role in osteosarcoma.
    Ning B, Liu Y, Huang T, Wei Y. Ning B, et al. Cancer Med. 2023 Mar;12(5):5676-5687. doi: 10.1002/cam4.5407. Epub 2023 Feb 15. Cancer Med. 2023. PMID: 36789748 Free PMC article. Review.
  • Efficacy of adjuvant radiotherapy in the intracranial hemangiopericytoma.
    Jeon SH, Park SH, Kim JW, Park CK, Paek SH, Kim IH. Jeon SH, et al. J Neurooncol. 2018 May;137(3):567-573. doi: 10.1007/s11060-018-2746-3. Epub 2018 Jan 11. J Neurooncol. 2018. PMID: 29327171
  • Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells.
    Mamo T, Mladek AC, Shogren KL, Gustafson C, Gupta SK, Riester SM, Maran A, Galindo M, van Wijnen AJ, Sarkaria JN, Yaszemski MJ. Mamo T, et al. Biochem Biophys Res Commun. 2017 Apr 29;486(2):307-313. doi: 10.1016/j.bbrc.2017.03.033. Epub 2017 Mar 12. Biochem Biophys Res Commun. 2017. PMID: 28300555 Free PMC article.
  • Update on Osteosarcoma.
    Belayneh R, Fourman MS, Bhogal S, Weiss KR. Belayneh R, et al. Curr Oncol Rep. 2021 Apr 21;23(6):71. doi: 10.1007/s11912-021-01053-7. Curr Oncol Rep. 2021. PMID: 33880674 Review.

Publication types

LinkOut - more resources